The DOI matches its Crossref record; 108 of the 108 references it cites were found in a registry or an index.
Histone acetyltransferases CBP/p300 in tumorigenesis and CBP/p300 inhibitors as promising novel anticancer agents
Open accessAbstract
The histone acetyltransferases CBP and p300, often referred to as CBP/p300 due to their sequence homology and functional overlap and co-operation, are emerging as critical drivers of oncogenesis in the past several years.CBP/p300 induces histone H3 lysine 27 acetylation (H3K27ac) at target gene promoters, enhancers and super-enhancers, thereby activating gene transcription.While earlier studies indicate that CBP/p300 deletion/loss can promote tumorigenesis, CBP/p300 have more recently been shown to be over-expressed in cancer cells and drug-resistant cancer cells, activate oncogene transcription and induce cancer cell proliferation, survival, tumorigenesis, metastasis, immune evasion and drug-resistance.Small molecule CBP/p300 histone acetyltransferase inhibitors, bromodomain inhibitors, CBP/p300 and BET bromodomain dual inhibitors and p300 protein degraders have recently been discovered.The CBP/p300 inhibitors and degraders reduce H3K27ac, down-regulate oncogene transcription, induce cancer cell growth inhibition and cell death, activate immune response, overcome drug resistance and suppress tumor progression in vivo.In addition, CBP/p300 inhibitors enhance the anticancer efficacy of chemotherapy, radiotherapy and epigenetic anticancer agents, including BET bromodomain inhibitors; and the combination therapies exert substantial anticancer effects in mouse models of human cancers including drug-resistant cancers.Currently, two CBP/p300 inhibitors are under clinical evaluation in patients with advanced and drug-resistant solid tumors or hematological malignancies.In summary, CBP/p300 have recently been identified as critical tumorigenic drivers, and CBP/p300 inhibitors and protein degraders are emerging as promising novel anticancer agents for clinical translation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Hou, X., Gong, R., Zhan, J., Zhou, T., Ma, Y., Zhao, Y., Zhang, Y., Chen, G., Zhang, Z., Ma, S., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4559-3 · Cited by 36
Self-citationRetractedMaster Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes
Whyte, W. A., Orlando, D. A., Hnisz, D., Abraham, B. J., Lin, C. Y., Kagey, M. H., Rahl, P. B., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.035 · Cited by 4,143
Super-enhancers in the control of cell identity and disease
Hnisz, D., Abraham, B. J., Lee, T. I., Lau, A., Saint-André, V., Sigova, A. A., Hoke, H. A., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.09.053 · Cited by 3,662
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.036 · Cited by 2,961
The Transcriptional Coactivators p300 and CBP Are Histone Acetyltransferases
Ogryzko, V. V., Schiltz, R. L., Russanova, V., Howard, B. H., & Nakatani, Y. (1996) · Cell · doi:10.1016/s0092-8674(00)82001-2 · Cited by 2,952
Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain
Gu, W., & Roeder, R. G. (1997) · Cell · doi:10.1016/s0092-8674(00)80521-8 · Cited by 2,559
The CBP co-activator is a histone acetyltransferase
Bannister, A. J., & Kouzarides, T. (1996) · Nature · doi:10.1038/384641a0 · Cited by 1,805
Catalytic in vivo protein knockdown by small-molecule PROTACs
Bondeson, D. P., Mares, A., Smith, I. E. D., Ko, E., Campos, S., Miah, A. H., Mulholland, K. E., Routly, N., Buckley, D. L., Gustafson, J. L., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1858 · Cited by 1,356
Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP
Petrif, F., Giles, R. H., Dauwerse, H. G., Saris, J. J., Hennekam, R. C. M., Masuno, M., Tommerup, N., van Ommen, G.-J. B., Goodman, R. H., Peters, D. J. M., et al. (1995) · Nature · doi:10.1038/376348a0 · Cited by 1,217
Jin, Q., Yu, L., Wang, L., Zhang, Z., Kasper, L. H., Lee, J., Wang, C., Brindle, P. K., Dent, S. Y. R., & Ge, K. (2011) · The EMBO Journal · doi:10.1038/emboj.2010.318 · Cited by 877
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours
Lasko, L. M., Jakob, C. G., Edalji, R. P., Qiu, W., Montgomery, D., Digiammarino, E. L., Hansen, T. M., Risi, R. M., Frey, R., Manaves, V., et al. (2017) · Nature · doi:10.1038/nature24028 · Cited by 858
An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element
Mansour, M. R., Abraham, B. J., Anders, L., Berezovskaya, A., Gutierrez, A., Durbin, A. D., Etchin, J., Lawton, L., Sallan, S. E., Silverman, L. B., et al. (2014) · Science · doi:10.1126/science.1259037 · Cited by 801
Eukaryotic core promoters and the functional basis of transcription initiation
Haberle, V., & Stark, A. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0028-8 · Cited by 774
Organization and regulation of gene transcription
Cramer, P. (2019) · Nature · doi:10.1038/s41586-019-1517-4 · Cited by 748
Regulation of activity of the transcription factor GATA-1 by acetylation
Boyes, J., Byfield, P., Nakatani, Y., & Ogryzko, V. (1998) · Nature · doi:10.1038/25166 · Cited by 694
Saito, A., Yamashita, T., Mariko, Y., Nosaka, Y., Tsuchiya, K., Ando, T., Suzuki, T., Tsuruo, T., & Nakanishi, O. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4592 · Cited by 694
Bowers, E. M., Yan, G., Mukherjee, C., Orry, A., Wang, L., Holbert, M. A., Crump, N. T., Hazzalin, C. A., Liszczak, G., Yuan, H., et al. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.03.006 · Cited by 666
Synergistic activation of transcription by CBP and p53
Gu, W., Shi, X.-L., & Roeder, R. G. (1997) · Nature · doi:10.1038/42972 · Cited by 596
CBP-mediated acetylation of histone H3 lysine 27 antagonizes Drosophila Polycomb silencing
Tie, F., Banerjee, R., Stratton, C. A., Prasad-Sinha, J., Stepanik, V., Zlobin, A., Diaz, M. O., Scacheri, P. C., & Harte, P. J. (2009) · Development · doi:10.1242/dev.037127 · Cited by 568
Balasubramanyam, K., Altaf, M., Varier, R. A., Swaminathan, V., Ravindran, A., Sadhale, P. P., & Kundu, T. K. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402839200 · Cited by 546
Small Molecule Modulators of Histone Acetyltransferase p300
Balasubramanyam, K., Swaminathan, V., Ranganathan, A., & Kundu, T. K. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301580200 · Cited by 515
Time-Resolved Analysis Reveals Rapid Dynamics and Broad Scope of the CBP/p300 Acetylome
Weinert, B. T., Narita, T., Satpathy, S., Srinivasan, B., Hansen, B. K., Schölz, C., Hamilton, W. B., Zucconi, B. E., Wang, W. W., Liu, W. R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.04.033 · Cited by 509
Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP
Kung, A. L., Rebel, V. I., Bronson, R. T., Ch'ng, L.-E., Sieff, C. A., Livingston, D. M., & Yao, T.-P. (2000) · Genes & Development · doi:10.1101/gad.14.3.272 · Cited by 440
The SWI/SNF chromatin remodelling complex is required for maintenance of lineage specific enhancers
Alver, B. H., Kim, K. H., Lu, P., Wang, X., Manchester, H. E., Wang, W., Haswell, J. R., Park, P. J., & Roberts, C. W. M. (2017) · Nature Communications · doi:10.1038/ncomms14648 · Cited by 427
RNA Binding to CBP Stimulates Histone Acetylation and Transcription
Bose, D. A., Donahue, G., Reinberg, D., Shiekhattar, R., Bonasio, R., & Berger, S. L. (2017) · Cell · doi:10.1016/j.cell.2016.12.020 · Cited by 426
Conservation between the RNA Polymerase I, II, and III Transcription Initiation Machineries
Vannini, A., & Cramer, P. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.01.023 · Cited by 425
Regulation of the p300 HAT domain via a novel activation loop
Thompson, P. R., Wang, D., Wang, L., Fulco, M., Pediconi, N., Zhang, D., An, W., Ge, Q., Roeder, R. G., Wong, J., et al. (2004) · Nature Structural & Molecular Biology · doi:10.1038/nsmb740 · Cited by 423
A Transcriptional Switch Mediated by Cofactor Methylation
Xu, W., Chen, H., Du, K., Asahara, H., Tini, M., Emerson, B. M., Montminy, M., & Evans, R. M. (2001) · Science · doi:10.1126/science.1065961 · Cited by 416
Pasini, D., Malatesta, M., Jung, H. R., Walfridsson, J., Willer, A., Olsson, L., Skotte, J., Wutz, A., Porse, B., Jensen, O. N., et al. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq244 · Cited by 401
Lau, O. D., Kundu, T. K., Soccio, R. E., Ait-Si-Ali, S., Khalil, E. M., Vassilev, A., Wolffe, A. P., Nakatani, Y., Roeder, R. G., & Cole, P. A. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)80452-9 · Cited by 394
The role of enhancers in cancer
Sur, I., & Taipale, J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.62 · Cited by 389
Enhancer Activity Requires CBP/P300 Bromodomain-Dependent Histone H3K27 Acetylation
Raisner, R., Kharbanda, S., Jin, L., Jeng, E., Chan, E., Merchant, M., Haverty, P. M., Bainer, R., Cheung, T., Arnott, D., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.07.041 · Cited by 375
Roe, J.-S., Mercan, F., Rivera, K., Pappin, D. J., & Vakoc, C. R. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.04.011 · Cited by 337
Structure of the p300 catalytic core and implications for chromatin targeting and HAT regulation
Delvecchio, M., Gaucher, J., Aguilar-Gurrieri, C., Ortega, E., & Panne, D. (2013) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2642 · Cited by 303
Stimulation of c‐MYC transcriptional activity and acetylation by recruitment of the cofactor CBP
Vervoorts, J., Lüscher‐Firzlaff, J. M., Rottmann, S., Lilischkis, R., Walsemann, G., Dohmann, K., Austen, M., & Lüscher, B. (2003) · EMBO reports · doi:10.1038/sj.embor.embor821 · Cited by 281
Discovery and Optimization of Small-Molecule Ligands for the CBP/p300 Bromodomains
Hay, D. A., Fedorov, O., Martin, S., Singleton, D. C., Tallant, C., Wells, C., Picaud, S., Philpott, M., Monteiro, O. P., Rogers, C. M., et al. (2014) · Journal of the American Chemical Society · doi:10.1021/ja412434f · Cited by 277
Targeting the p300/CBP Axis in Lethal Prostate Cancer
Welti, J., Sharp, A., Brooks, N., Yuan, W., McNair, C., Chand, S. N., Pal, A., Figueiredo, I., Riisnaes, R., Gurel, B., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0751 · Cited by 275
The acetyltransferase activity of CBP stimulates transcription
Martínez‐Balbás, M. A., Bannister, A. J., Martin, K., Haus‐Seuffert, P., Meisterernst, M., & Kouzarides, T. (1998) · The EMBO Journal · doi:10.1093/emboj/17.10.2886 · Cited by 266
Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors
Huang, X., Yan, J., Zhang, M., Wang, Y., Chen, Y., Fu, X., Wei, R., Zheng, X.-L., Liu, Z., Zhang, X., et al. (2018) · Cell · doi:10.1016/j.cell.2018.08.058 · Cited by 264
Self-citationCBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses
Hammitzsch, A., Tallant, C., Fedorov, O., O’Mahony, A., Brennan, P. E., Hay, D. A., Martinez, F. O., Al-Mossawi, M. H., de Wit, J., Vecellio, M., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1501956112 · Cited by 254
Wang, S.-P., Tang, Z., Chen, C.-W., Shimada, M., Koche, R. P., Wang, L.-H., Nakadai, T., Chramiec, A., Krivtsov, A. V., Armstrong, S. A., et al. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.06.028 · Cited by 251
Distinct roles for CREB-binding protein and p300 in hematopoietic stem cell self-renewal
Rebel, V. I., Kung, A. L., Tanner, E. A., Yang, H., Bronson, R. T., & Livingston, D. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.232568499 · Cited by 244
Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy
Picaud, S., Fedorov, O., Thanasopoulou, A., Leonards, K., Jones, K., Meier, J., Olzscha, H., Monteiro, O., Martin, S., Philpott, M., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0236 · Cited by 229
Narita, T., Ito, S., Higashijima, Y., Chu, W. K., Neumann, K., Walter, J., Satpathy, S., Liebner, T., Hamilton, W. B., Maskey, E., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.03.008 · Cited by 228
Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity
Stimson, L., Rowlands, M. G., Newbatt, Y. M., Smith, N. F., Raynaud, F. I., Rogers, P., Bavetsias, V., Gorsuch, S., Jarman, M., Bannister, A., et al. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0135 · Cited by 223
Inhibition of p300 impairs Foxp3+ T regulatory cell function and promotes antitumor immunity
Liu, Y., Wang, L., Predina, J., Han, R., Beier, U. H., Wang, L.-C. S., Kapoor, V., Bhatti, T. R., Akimova, T., Singhal, S., et al. (2013) · Nature Medicine · doi:10.1038/nm.3286 · Cited by 201
Kundu, T. K., Palhan, V. B., Wang, Z., An, W., Cole, P. A., & Roeder, R. G. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00054-x · Cited by 201
DUX4 recruits p300/CBP through its C-terminus and induces global H3K27 acetylation changes
Choi, S. H., Gearhart, M. D., Cui, Z., Bosnakovski, D., Kim, M., Schennum, N., & Kyba, M. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw141 · Cited by 196
A transcription-factor-binding surface of coactivator p300 is required for haematopoiesis
Kasper, L. H., Boussouar, F., Ney, P. A., Jackson, C. W., Rehg, J., van Deursen, J. M., & Brindle, P. K. (2002) · Nature · doi:10.1038/nature01062 · Cited by 193
Lai, B., Lee, J.-E., Jang, Y., Wang, L., Peng, W., & Ge, K. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx234 · Cited by 191
Ogiwara, H., Sasaki, M., Mitachi, T., Oike, T., Higuchi, S., Tominaga, Y., & Kohno, T. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0754 · Cited by 182
mTORC1 Phosphorylates Acetyltransferase p300 to Regulate Autophagy and Lipogenesis
Wan, W., You, Z., Xu, Y., Zhou, L., Guan, Z., Peng, C., Wong, C. C. L., Su, H., Zhou, T., Xia, H., et al. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.09.020 · Cited by 177
Transcription factor dimerization activates the p300 acetyltransferase
Ortega, E., Rengachari, S., Ibrahim, Z., Hoghoughi, N., Gaucher, J., Holehouse, A. S., Khochbin, S., & Panne, D. (2018) · Nature · doi:10.1038/s41586-018-0621-1 · Cited by 175
Phosphorylation of histone H3.3 at serine 31 promotes p300 activity and enhancer acetylation
Martire, S., Gogate, A. A., Whitmill, A., Tafessu, A., Nguyen, J., Teng, Y.-C., Tastemel, M., & Banaszynski, L. A. (2019) · Nature Genetics · doi:10.1038/s41588-019-0428-5 · Cited by 175
Short-chain fatty acids activate acetyltransferase p300
Thomas, S. P., & Denu, J. M. (2021) · eLife · doi:10.7554/elife.72171 · Cited by 171
Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition
Hogg, S. J., Motorna, O., Cluse, L. A., Johanson, T. M., Coughlan, H. D., Raviram, R., Myers, R. M., Costacurta, M., Todorovski, I., Pijpers, L., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.04.015 · Cited by 170
Cai, L.-Y., Chen, S.-J., Xiao, S.-H., Sun, Q.-J., Ding, C.-H., Zheng, B.-N., Zhu, X.-Y., Liu, S.-Q., Yang, F., Yang, Y.-X., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-1323 · Cited by 169
Self-citationVHL Deficiency Drives Enhancer Activation of Oncogenes in Clear Cell Renal Cell Carcinoma
Yao, X., Tan, J., Lim, K. J., Koh, J., Ooi, W. F., Li, Z., Huang, D., Xing, M., Chan, Y. S., Qu, J. Z., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0375 · Cited by 166
Tang, Z., Chen, W.-Y., Shimada, M., Nguyen, U. T. T., Kim, J., Sun, X.-J., Sengoku, T., McGinty, R. K., Fernandez, J. P., Muir, T. W., et al. (2013) · Cell · doi:10.1016/j.cell.2013.06.027 · Cited by 165
Brd4 and P300 Confer Transcriptional Competency during Zygotic Genome Activation
Chan, S. H., Tang, Y., Miao, L., Darwich‐Codore, H., Vejnar, C. E., Beaudoin, J.-D., Musaev, D., Fernández, J. P., Benitez, M. D. J., Bazzini, A., et al. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.05.037 · Cited by 165
Histone Acetyltransferase p300 Induces De Novo Super-Enhancers to Drive Cellular Senescence
Sen, P., Lan, Y., Li, C. Y., Sidoli, S., Donahue, G., Dou, Z., Frederick, B., Chen, Q., Luense, L. J., Garcia, B. A., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.01.021 · Cited by 164
Self-citationEP300 Selectively Controls the Enhancer Landscape of MYCN -Amplified Neuroblastoma
Durbin, A. D., Wang, T., Wimalasena, V. K., Zimmerman, M. W., Li, D., Dharia, N. V., Mariani, L., Shendy, N. A. M., Nance, S., Patel, A. G., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0385 · Cited by 162
Aberrant Super‐Enhancer Landscape in Human Hepatocellular Carcinoma
Tsang, F. H., Law, C., Tang, T. C. C., Cheng, C. L., Chin, D. W., Tam, V., Wei, L., Wong, C. C., Ng, I. O., & Wong, C. (2019) · Hepatology · doi:10.1002/hep.30544 · Cited by 161
Jin, L., Garcia, J., Chan, E., de la Cruz, C., Segal, E., Merchant, M., Kharbanda, S., Raisner, R., Haverty, P. M., Modrusan, Z., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0314 · Cited by 153
Butyrate Promotes Induced Pluripotent Stem Cell Generation
Liang, G., Taranova, O., Xia, K., & Zhang, Y. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.142059 · Cited by 149
Romero, F. A., Murray, J. M., Lai, K. W., Tsui, V., Albrecht, B. K., An, L., Beresini, M. H., Boenig, G. D. L., Bronner, S. M., Chan, E. W., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00796 · Cited by 146
Qian, M., Zhang, H., Kham, S. K. Y., Liu, S., Jiang, C., Zhao, X., Lü, Y., Goodings, C., Lin, T.-N., Zhang, R., et al. (2016) · Genome Research · doi:10.1101/gr.209163.116 · Cited by 141
Solution structure of the TAZ2 (CH3) domain of the transcriptional adaptor protein CBP
Guzman, R. N. D., Liu, H. Y., Martinez‐Yamout, M. A., Dyson, H. J., & Wright, P. E. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.4141 · Cited by 135
Yang, Y., Zhang, R., Li, Z., Mei, L., Wan, S., Ding, H., Chen, Z., Xing, J., Feng, H., Han, J., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01721 · Cited by 132
Transcription factor‐dependent regulation of CBP and P/CAF histone acetyltransferase activity
Soutoglou, E., Viollet, B., Vaxillaire, M., Yaniv, M., Pontoglio, M., & Talianidis, I. (2001) · The EMBO Journal · doi:10.1093/emboj/20.8.1984 · Cited by 125
Wu, T., Kamikawa, Y. F., & Donohoe, M. E. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.10.003 · Cited by 124
Tie, F., Banerjee, R., Saiakhova, A., Howard, B., Monteith, K. E., Scacheri, P. C., Cosgrove, M. S., & Harte, P. J. (2014) · Development · doi:10.1242/dev.102392 · Cited by 121
Xiao, Y., Nagai, Y., Deng, G., Ohtani, T., Zhu, Z., Zhou, Z., Zhang, H., Ji, M. Q., Lough, J., Samanta, A., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.04.021 · Cited by 116
The PHD Type Zinc Finger Is an Integral Part of the CBP Acetyltransferase Domain
Kalkhoven, E., Teunissen, H., Houweling, A., Verrijzer, C. P., & ZANTEMA, A. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.7.1961-1970.2002 · Cited by 114
Loss of CBP causes T cell lymphomagenesis in synergy with p27Kip1 insufficiency
Kang, N., Tong, C., Boussouar, F., Baker, D. J., Xu, W., Leontovich, A. A., Taylor, W. R., Brindle, P. K., & van Deursen, J. M. A. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00022-4 · Cited by 110
Giotopoulos, G., Chan, W.-I., Horton, S. J., Ruau, D., Gallipoli, P., Fowler, A., Crawley, C. R., Papaemmanuil, E., Campbell, P., Göttgens, B., et al. (2015) · Oncogene · doi:10.1038/onc.2015.92 · Cited by 108
Wang, Y.-C., Wu, Y.-S., Hung, C.-Y., Wang, S.-A., Young, M., Hsu, T.-I., & Hung, J.-J. (2018) · Nature Communications · doi:10.1038/s41467-018-06178-1 · Cited by 108
JMJD6 is a tumorigenic factor and therapeutic target in neuroblastoma
Wong, M., Sun, Y., Xi, Z., Milazzo, G., Poulos, R. C., Bartenhagen, C., Bell, J. L., Mayoh, C., Ho, N., Tee, A. E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11132-w · Cited by 106
Self-citationAn, W., Palhan, V. B., Karymov, M. A., Leuba, S. H., & Roeder, R. G. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00497-5 · Cited by 100
Bromodomain inhibition of the coactivators CBP/EP300 facilitate cellular reprogramming
Ebrahımı, A., Sevinç, K., Sevinç, G. G., Cribbs, A. P., Philpott, M., Uyulur, F., Morova, T., Dunford, J. E., Göklemez, S., Arı, Ş., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0264-z · Cited by 100
Bordoli, L., Hüsser, S., Lüthi, U., Netsch, M., Osmani, H., & Eckner, R. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.21.4462 · Cited by 99
Oike, T., Komachi, M., Ogiwara, H., Amornwichet, N., Saitoh, Y., Torikai, K., Kubo, N., Nakano, T., & Kohno, T. (2014) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2014.03.015 · Cited by 98
A noncanonical AR addiction drives enzalutamide resistance in prostate cancer
He, Y., Wei, T., Ye, Z., Orme, J. J., Lin, D., Sheng, H., Fazli, L., Karnes, R. J., Jiménez, R. E., Wang, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21860-7 · Cited by 95
Liu, Y., Wang, L., Han, R., Beier, U. H., Akimova, T., Bhatti, T. R., Xiao, H., Cole, P. A., Brindle, P. K., & Hancock, W. W. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.00919-14 · Cited by 93
Yokomizo, C., Yamaguchi, K., Itoh, Y., Nishimura, T., Umemura, A., Minami, M., Yasui, K., Mitsuyoshi, H., Fujii, H., Tochiki, N., et al. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.06.030 · Cited by 84
Regulatory T Cell Modulation by CBP/EP300 Bromodomain Inhibition
Ghosh, S., Taylor, A. M., Chin, M., Huang, H.-R., Conery, A. R., Mertz, J. A., Salmerón, A., Dakle, P. J., Mele, D. A., Côté, A., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.708560 · Cited by 83
Role of the CBP catalytic core in intramolecular SUMOylation and control of histone H3 acetylation
Park, S., Stanfield, R. L., Martinez‐Yamout, M. A., Dyson, H. J., Wilson, I. A., & Wright, P. E. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1703105114 · Cited by 82
The ZZ domain of p300 mediates specificity of the adjacent HAT domain for histone H3
Zhang, Y., Xue, Y., Shi, J., Ahn, J., Mi, W., Ali, M., Wang, X., Klein, B. J., Wen, H., Li, W., et al. (2018) · Nature Structural & Molecular Biology · doi:10.1038/s41594-018-0114-9 · Cited by 82
Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734
Spriano, F., Gaudio, E., Cascione, L., Tarantelli, C., Melle, F., Motta, G., Priebe, V., Rinaldi, A., Golino, G., Mensah, A. A., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001879 · Cited by 78
Nagata, D. D. A., Chiang, E. Y., Jhunjhunwala, S., Caplazi, P., Arumugam, V., Modrusan, Z. D., Chan, E. W., Merchant, M. A., Jin, L., Arnott, D. P., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.03.008 · Cited by 75
Huang, Y., Mouttet, B., Warnatz, H.-J., Risch, T., Rietmann, F., Frommelt, F., Ngo, Q. A., Dobay, M. P., Marovca, B., Jenni, S., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.10.004 · Cited by 63
CREBBP/EP300 bromodomains are critical to sustain the GATA1/MYC regulatory axis in proliferation
García-Carpizo, V., Ruiz‐Llorente, S., Sarmentero, J., Graña‐Castro, O., Pisano, D. G., & Barrero, M. J. (2018) · Epigenetics & Chromatin · doi:10.1186/s13072-018-0197-x · Cited by 60
Polycomb inhibits histone acetylation by CBP by binding directly to its catalytic domain
Tie, F., Banerjee, R., Fu, C. S., Stratton, C. A., Fang, M., & Harte, P. J. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1515465113 · Cited by 57
Combination Targeting of the Bromodomain and Acetyltransferase Active Site of p300/CBP
Zucconi, B. E., Makofske, J. L., Meyers, D. J., Hwang, Y., Wu, M., Kuroda, M. I., & Cole, P. A. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00160 · Cited by 56
MITF Expression Predicts Therapeutic Vulnerability to p300 Inhibition in Human Melanoma
Kim, E. J., Zucconi, B. E., Wu, M., Nocco, S. E., Meyers, D. J., McGee, J. S., Venkatesh, S., Cohen, D. L., Gonzalez, E. C., Ryu, B., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2331 · Cited by 55
Zhang, Y., Brown, K., Yu, Y., Ibrahim, Z., Zandian, M., Xuan, H., Ingersoll, S., Lee, T., Ebmeier, C. C., Liu, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24950-8 · Cited by 55
Therapeutic targeting of p300/CBP HAT domain for the treatment of NUT midline carcinoma
Zhang, X., Zegar, T., Lucas, A., Morrison-Smith, C. D., Knox, T. M., French, C. A., Knapp, S., Müller, S., & Siveke, J. T. (2020) · Oncogene · doi:10.1038/s41388-020-1301-9 · Cited by 50
Self-citationChen, J., Nelson, C. B., Wong, M., Tee, A. E., Liu, P. Y., La, T., Fletcher, J. I., Kamili, A., Mayoh, C., Bartenhagen, C., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3044 · Cited by 46
Self-citationLoss of p300 accelerates MDS-associated leukemogenesis
Cheng, G., Liu, F., Asai, T., Lai, F., Man, N., Xu, H., Chen, S., Greenblatt, S. M., Hamard, P.-J., Ando, K., et al. (2016) · Leukemia · doi:10.1038/leu.2016.347 · Cited by 42
DYRK1A interacts with histone acetyl transferase p300 and CBP and localizes to enhancers
Li, S., Chu, X., Fu, Y., Lei, P., Yao, Y., Yang, W., Zhang, Y., Washburn, M. P., Florens, L. A., Jaiswal, M., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky754 · Cited by 39
The PHD finger of p300 Influences Its Ability to Acetylate Histone and Non-Histone Targets
Rack, J. G. M., Lutter, T., Bjerga, G. E. K., Guder, C., Ehrhardt, C., Värv, S., Ziegler, M., & Aasland, R. (2014) · Journal of Molecular Biology · doi:10.1016/j.jmb.2014.08.011 · Cited by 37
van Gils, N., Martiáñez, T., Vermue, E., Rutten, A. P., Denkers, F., van der Deure, T., Ossenkoppele, G. J., Giles, F. J., & Smit, L. (2021) · HemaSphere · doi:10.1097/hs9.0000000000000610 · Cited by 37
Haery, L., Lugo-Pico, J. G., Henry, R. A., Andrews, A. J., & Gilmore, T. D. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-29 · Cited by 33
Strachowska, M., Gronkowska, K., Michlewska, S., & Robaszkiewicz, A. (2021) · Cancers · doi:10.3390/cancers13184614 · Cited by 30
Wu, F., Hua, Y., Kaochar, S., Nie, S., Lin, Y.-L., Yao, Y., Wu, J., Wu, X., Fu, X., Schiff, R., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b02164 · Cited by 29
Diesch, J., Pannérer, M.-M. L., Winkler, R., Casquero, R., Muhar, M., van der Garde, M., Maher, M., Herraez, C. M., Bech‐Serra, J. J., Fellner, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26258-z · Cited by 28
Roeder, R. G., Tang, Z., Kim, J., Muir, T. W., Sun, X., Shimada, M., Chen, W.-Y., Fernandez, J., McGinty, R. K., Sengoku, T., et al. (2022) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/r1sc-qz45 · Cited by 9
Haery, L., Mussakhan, S., Waxman, D. J., et al. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2016.1160083 · Cited by 4
Cited by
Jiang, C., Zhu, Y., Chen, H., Lin, J., Xie, R., Li, W., Xue, J., Chen, L., Chen, X., & Xu, S. (2023) · Cell Death & Disease · doi:10.1038/s41419-023-06181-5 · Cited by 36
Metadata
- Authors
- Chen, Q., Yang, B., Liu, X., Zhang, X. D., Zhang, L., & Liu, T.
- Venue
- Theranostics
- Publisher
- Ivyspring International Publisher
- Published
- 2022
- Volume
- 12
- Issue
- 11
- Pages
- 4935-4948
- ISSN
- 1838-7640 (ISSN-L)
- OpenAlex
- W4285146377
- Cited by
- 261
- References
- 108
- FWCI
- 13.60
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.